Abstract

Objective: Objective of current narrative review is to mainly evaluate existing and future developments on basis of pharmacokinetic rules for manufacturing of safe and effective therapeutic molecule during drug design and should take possible actions to standardize modifications.
Methodology: In order to write a review; literature has been collected from 2000 to 2024. Data synthesized by PRISMA methodology. Grading-of-Recommendation-Assessment-Development-and-Evaluation criteria were employed for establishing the quality of literature. The review demonstrated the pharmacokinetic aspects of structural modification in drug design.
Results: Structural modification resulted in enhanced of activity of phenothiazine, estradiol, ibuprofen, galeterone and endomorphines; reduction in toxicity of l-ethambutol and cetrizine; enhancement of drug delivery of diclofenac; increase anti-nitrosating effect of unsaturated fattyacids, penolics and tocopherols from EVOO (Extra Virgin Olive Oil); and derivation of nucleic acid drugs i.e. N-methyladenosine and peptide nucleic acids.
Conclusion: Structural modifications bring safe pharmacokinetic data of many drugs and revolutionize pharmaceuticals to treat many of diseases. In future many drugs based on modification of structure (pro-drugs) will be available for use of patients with efficiency and safety to improve quality of life. There is a dire need of collaboration of academia and industries to provide various experimental settings and disseminate datasets.